Bristol Myers Squibb has won European Commission expanded approval of its CAR-T cell therapy Breyanzi in the blood cancer lymphoma.

Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T ...

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

William Blair upped their Q2 2025 earnings estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

William Blair raised their Q3 2026 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the ...

This was the stock's second consecutive day of losses.

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Bristol Myers Squibb’s dividend yield crossed the 4% mark, making it an attractive option for income-focused investors. The ...

2seventy bio makes the NASDAQ top percentage gainer list on acquisition news, currently trading at $4.9500, up 2.1500,gaining 76.7857% on volume of over 30 Million shares.

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...